STOCK TITAN

Vor Biopharma Inc - VOR STOCK NEWS

Welcome to our dedicated news page for Vor Biopharma (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vor Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vor Biopharma's position in the market.

Rhea-AI Summary
Vor Bio (VOR) Reports Positive Clinical Data and Financial Results, Anticipates Upcoming Milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
earnings
-
Rhea-AI Summary
Vor Bio, a clinical-stage cell and genome engineering company, has granted stock options and restricted stock units (RSUs) to four newly hired employees. The stock options allow the purchase of 50,000 shares of Vor Bio's common stock at an exercise price of $2.08 per share. The RSUs represent the right to receive 75,000 shares of Vor Bio's common stock. Both the stock options and RSUs will vest over a four-year period, subject to continued employment with Vor Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will participate in upcoming investor conferences, including the Stifel 2023 Healthcare Conference, the 6th Annual Evercore ISI HealthCONx Conference, and the Piper Sandler 35th Annual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.43%
Tags
conferences
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) announced that preclinical and clinical data supporting their novel platform for treating acute myeloid leukemia (AML) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting. The data includes updates from the VBP101 clinical trial and the CD33CART study, as well as other studies on AML profiling and the collaboration with Janssen. Vor Bio's CEO expressed confidence in the progress made and the potential of their next-generation transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
none
-
Rhea-AI Summary
Vor Bio grants stock options and RSUs to new employees as inducements to employment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary
Vor Bio to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) to participate in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.4%
Tags
earnings
-
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on August 8-9, 2023, at Lotte Palace Hotel in New York, NY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
none
Vor Biopharma Inc

Nasdaq:VOR

VOR Rankings

VOR Stock Data

161.56M
31.85M
1.25%
88.5%
4.5%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About VOR

vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar